Neuronetics, Inc. (STIM) Stock

Neuronetics, Inc. (STIM) is a Healthcare stock trading at $3.09 (as of 2026-08-20), with a market capitalization of $215.03M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.

Understand Neuronetics, Inc.: how it makes money

Neuronetics develops and markets the NeuroStar Advanced Therapy System, a non-invasive office-based treatment that uses transcranial magnetic stimulation to treat adult patients with major depressive disorder, and it generates revenue tied to both NeuroStar treatment sessions and its system sales.

NeuroStar revenue is primarily driven by how many Active Sites deliver NeuroStar treatment sessions, with treatment-session volume supported by an installed base reflected in Active Sites and cumulative treatment activity (All-Time Treatment Sessions).

Business quality (Weak): The company has a clear operational track tied to Active Sites and NeuroStar treatment sessions, but profitability remains weak in the latest quarter (operating margin is negative).

Bull case

  • Large demonstrated clinical adoption over time: All-Time Treatment Sessions are 8,200,000 and All-Time Patients Treated are 229,429.
  • Material gross profitability in the latest quarter: Gross margin is 46.9% for the period ended 2026-03-31.

Bear case

  • Operating losses persist: Operating margin is -26.1% for the period ended 2026-03-31.
  • Revenue in the latest quarter appears small and potentially uneven across components: Consolidated Revenue is 0.03 USD_B, while NeuroStar Advanced Therapy System Revenue is shown as 0.0 USD_B in the provided KPI set.
Valuation — source: SEC EDGAR (first-party)
Price$3.09
Market Cap$215.03M
Price / Book9.94
Price / Sales1.46
FCF Yield-14.1%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$149.16M
Net Margin-26.1%
Revenue Growth (YoY)99.2%
EPS Growth (YoY)-57.2%
FCF Growth (YoY)-34.8%
Financial Health — source: SEC EDGAR
Altman Z-Score-2.84 (distress)
Piotroski F-Score4/9 (moderate)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.6
Industry P/E (Medical Equipment)32.9
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderMadryn Asset Management, LP ($26.79M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryMedical Equipment
CEOKeith J. Sullivan
Employees716
CountryUS
IPO Date2018-06-28

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

  • Orchestra BioMed Holdings, Inc. (OBIO)
  • AVITA Medical, Inc. (RCEL)
  • OraSure Technologies, Inc. (OSUR)
  • InfuSystem Holdings, Inc. (INFU)
  • Utah Medical Products, Inc. (UTMD)
  • Pro-Dex, Inc. (PDEX)
  • Lucid Diagnostics Inc. (LUCD)
  • IceCure Medical Ltd (ICCM)
STIM earnings history · STIM institutional & insider holders · STIM KPIs & operating metrics · STIM financials · STIM investor presentations & press releases · STIM SEC filings · STIM peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-20.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.